Bronchodilation by an inhaled VPAC(2) receptor agonist in XXXX with stable @entity565 .

@entity1 @entity6891 @entity62807 @entity565 @entity840 @entity972 @entity6410
BACKGROUND: The synthetic vasoactive intestinal peptide ( @entity6891 ) analogue Ro 25-1553 is a selective @entity6891 -PACAP type 2 (VPAC(2)) receptor agonist that causes a bronchodilatory effect in @entity840 in vivo. The effect of Ro 25-1553 given by inhalation to @entity1 with @entity565 was studied and compared with that of a long acting beta(2) adrenoceptor agonist. METHODS: Twenty four @entity1 with moderate stable @entity565 participated in a double blind, randomised, placebo controlled, crossover study. The primary variable was bronchodilatory effect (increase in forced expiratory volume in 1 second, FEV(1)) after inhalation of Ro 25-1553 (100 microg or 600 microg) and @entity6410 (4.5 microg), respectively. Putative side effects were characterised by monitoring sitting blood pressure, serum @entity972 , electrocardiography and echocardiography. RESULTS: Inhalation of 600 microg Ro 25-1553 caused a rapid bronchodilatory effect (geometric mean increase in FEV(1) compared with placebo) within 3 minutes of 6% (95% CI 4 to 9), as did inhalation of @entity6410 (8% (95% CI 5 to 10)). The corresponding maximum bronchodilatory effect during 24 hours was similar for 600 microg Ro 25-1553 (7% (95% CI 4 to 10)) and the reference bronchodilator @entity6410 (10% (95% CI 7 to 12)). However, for both doses of Ro 25-1553 the bronchodilatory effect was attenuated 5 hours after inhalation whereas @entity6410 still had a bronchodilatory effect 12 hours after inhalation. Neither @entity62807 nor @entity6410 produced any clinically relevant side effects. No drug related difference in adverse events was observed. CONCLUSION: Inhalation of a synthetic selective VPAC(2) receptor agonist constitutes a promising approach for bronchodilation in @entity1 with @entity565 .
